{"product_id":"global-neurological-drugs-market-growth-2023-2029","title":"Global Neurological Drugs Market Growth 2023-2029","description":"\u003cp\u003eGlobal Neurological Drugs Market Growth 2023-2029\u003cbr\u003e\nThe global Neurological Drugs market size is projected to grow from US$ 115430 million in 2022 to US$ 193720 million in 2029; it is expected to grow at a CAGR of 7.7% from 2023 to 2029.\u003c\/p\u003e\n\n\u003cp\u003eUnited States market for Neurological Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003c\/p\u003e\n\n\u003cp\u003eChina market for Neurological Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003c\/p\u003e\n\n\u003cp\u003eEurope market for Neurological Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003c\/p\u003e\n\n\u003cp\u003eGlobal key Neurological Drugs players cover Pfizer, Ely Lilly, Actavis, Mylan, Randox, Intellipharmaceutics, Astrazeneca, Lundbeck and Allergan, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.\u003c\/p\u003e\n\n\u003cp\u003eNervous system diseases are diseases that occur in the central nervous system, peripheral nervous system, and autonomic nervous system, mainly manifested in sensory, motor, consciousness, and autonomic dysfunction.\u003c\/p\u003e\n\n\u003cp\u003eLPI (LP Information)' newest research report, the “Neurological Drugs Industry Forecast” looks at past sales and reviews total world Neurological Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Neurological Drugs sales for 2023 through 2029. With Neurological Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neurological Drugs industry.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report provides a comprehensive analysis of the global Neurological Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M\u0026amp;A activity. This report also analyzes the strategies of leading global companies with a focus on Neurological Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Neurological Drugs market.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neurological Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neurological Drugs.\u003c\/p\u003e\n\n\u003cp\u003eThis report presents a comprehensive overview, market shares, and growth opportunities of Neurological Drugs market by product type, application, key manufacturers and key regions and countries.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation:\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by type\u003cbr\u003e\nNon-prescription drugs\u003cbr\u003e\nPrescription\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by application\u003cbr\u003e\nHospital\u003cbr\u003e\nClinic\u003c\/p\u003e\n\n\u003cp\u003eThis report also splits the market by region:\u003cbr\u003e\nAmericas\u003cbr\u003e\nUnited States\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\nBrazil\u003cbr\u003e\nAPAC\u003cbr\u003e\nChina\u003cbr\u003e\nJapan\u003cbr\u003e\nKorea\u003cbr\u003e\nSoutheast Asia\u003cbr\u003e\nIndia\u003cbr\u003e\nAustralia\u003cbr\u003e\nEurope\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nUK\u003cbr\u003e\nItaly\u003cbr\u003e\nRussia\u003cbr\u003e\nMiddle East \u0026amp; Africa\u003cbr\u003e\nEgypt\u003cbr\u003e\nSouth Africa\u003cbr\u003e\nIsrael\u003cbr\u003e\nTurkey\u003cbr\u003e\nGCC Countries\u003c\/p\u003e\n\n\u003cp\u003eThe below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.\u003cbr\u003e\nPfizer\u003cbr\u003e\nEly Lilly\u003cbr\u003e\nActavis\u003cbr\u003e\nMylan\u003cbr\u003e\nRandox\u003cbr\u003e\nIntellipharmaceutics\u003cbr\u003e\nAstrazeneca\u003cbr\u003e\nLundbeck\u003cbr\u003e\nAllergan\u003cbr\u003e\nGSK\u003cbr\u003e\nOtsuka Pharmaceutical\u003cbr\u003e\nTakeda\u003cbr\u003e\nNHU Group\u003cbr\u003e\nShionogi\u003cbr\u003e\nAPOTEX\u003cbr\u003e\nNorth China Pharmaceutical\u003cbr\u003e\nHarbin Pharmaceutical Co., Ltd.\u003cbr\u003e\nLukang Pharmaceutical\u003cbr\u003e\nKelun Pharmaceutical\u003cbr\u003e\nKehua Biology\u003c\/p\u003e\n\n\u003cp\u003eKey Questions Addressed in this Report\u003c\/p\u003e\n\n\u003cp\u003eWhat is the 10-year outlook for the global Neurological Drugs market?\u003c\/p\u003e\n\n\u003cp\u003eWhat factors are driving Neurological Drugs market growth, globally and by region?\u003c\/p\u003e\n\n\u003cp\u003eWhich technologies are poised for the fastest growth by market and region?\u003c\/p\u003e\n\n\u003cp\u003eHow do Neurological Drugs market opportunities vary by end market size?\u003c\/p\u003e\n\n\u003cp\u003eHow does Neurological Drugs break out type, application?\u003c\/p\u003e\n\n\u003cp\u003eWhat are the influences of COVID-19 and Russia-Ukraine war?\u003c\/p\u003e\n\n\u003cp\u003ePlease note: The report will take approximately 2 business days to prepare and deliver.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"June, 2023 \/ 123 Pages \/ MCW16230684","offer_id":47647151128882,"sku":null,"price":4392.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-neurological-drugs-market-growth-2023-2029","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}